Predictors of the placebo response in clinical trials on Parkinson's disease: A meta-analysis

Parkinsonism and Related Disorders

Volumn 29, Issue , 2016, Pages 83-89

  Shin, Chae Won ^a   Hahn, Seokyung ^a   Park, Byung Joo ^b   Kim, Jong Min ^c   Park, Eun Ok ^a   Jeon, Beomseok ^a  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

Author keywords

Meta analysis; Parkinson's disease; Placebo; Randomized clinical trials

Indexed keywords

ANTIPARKINSON AGENT; LEVODOPA; PLACEBO;

CLINICAL TRIAL (TOPIC); HUMAN; META ANALYSIS; PARKINSON DISEASE; PREDICTIVE VALUE; PSYCHOLOGY; SEVERITY OF ILLNESS INDEX;

ANTIPARKINSON AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; LEVODOPA; PARKINSON DISEASE; PLACEBOS; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX;

EID: 84969916586     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2016.05.019     Document Type: Article

References (30)

1. [1] de la Fuente-Fernandez, R., Schulzer, M., Stoessl, A.J., The placebo effect in neurological disorders. Lancet Neurol. 1 (2002), 85–91.
2. [2] Benedetti, F., Placebo-induced improvements: how therapeutic rituals affect the patient's brain. J. Acupunct. Meridian Stud. 5 (2012), 97–103.
3. [3] Colloca, L., Miller, F.G., The nocebo effect and its relevance for clinical practice. Psychosom. Med. 73 (2011), 598–603.
4. [4] Stathis, P., Smpiliris, M., Konitsiotis, S., Mitsikostas, D.D., Nocebo as a potential confounding factor in clinical trials for Parkinson's disease treatment: a meta-analysis. Eur. J. Neurol. 20 (2013), 527–533.
5. [5] Fahn, S., Elton, R.L., Unified Parkinson's disease rating Scale. Fahn S, G.M., Marsden, D., Calne, D.B., (eds.) Recent Developments in Parkinson's Disease, vol. 2, 1987, Macmillan Heathcare Information, Florham Park, NJ, 153–163.
6. [6] Shetty, N., Friedman, J.H., Kieburtz, K., Marshall, F.J., Oakes, D., The placebo response in Parkinson's disease. Clin. Neuropharmacol. 22 (1999), 207–212.
7. [7] Goetz, C.G., Leurgans, S., Raman, R., Stebbins, G.T., Objective changes in motor function during placebo treatment in PD. Neurology 54 (2000), 710–714.
8. [8] Goetz, C.G., Leurgans, S., Raman, R., Group, P.S., Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson's disease. Mov. Disord. 17 (2002), 283–288.
9. [9] Goetz, C.G., Wuu, J., McDermott, M.P., Adler, C.H., Fahn, S., Freed, C.R., et al. Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Mov. Disord. 23 (2008), 690–699.
10. [10] Walsh, B.T., Seidman, S.N., Sysko, R., Gould, M., Placebo response in studies of major depression: variable, substantial, and growing. JAMA 287 (2002), 1840–1847.
11. [11] Dunlop, B.W., Thase, M.E., Wun, C.C., Fayyad, R., Guico-Pabia, C.J., Musgnung, J., et al. A meta-analysis of factors impacting detection of antidepressant efficacy in clinical trials: the importance of academic sites. Neuropsychopharmacology 37 (2012), 2830–2836.
12. [12] Fox, S.H., Katzenschlager, R., Lim, S.Y., Ravina, B., Seppi, K., Coelho, M., et al. The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease. Mov. Disord. 26:Suppl. 3 (2011), S2–S41.
13. [13] Higgins, J.P., Green, S., Cochrane Handbook for Systematic Reviews of Interventions. 2011, The Cochrane Collaboration Available from: http://handbook.cochrane.org Version 5.1.0 [updated March 2011].
14. [14] Mestre, T.A., Shah, P., Marras, C., Tomlinson, G., Lang, A.E., Another face of placebo: the lessebo effect in Parkinson disease: meta-analyses. Neurology 82 (2014), 1402–1409.
15. [15] Sampaio, C., Bronzova, J., Hauser, R.A., Lang, A.E., Rascol, O., van de Witte, S.V., et al. Pardoprunox in early Parkinson's disease: results from 2 large, randomized double-blind trials. Mov. Disord. 26 (2011), 1464–1476.
16. [16] Lees, A., Fahn, S., Eggert, K.M., Jankovic, J., Lang, A., Micheli, F., et al. Perampanel, an AMPA antagonist, found to have no benefit in reducing “off” time in Parkinson's disease. Mov. Disord. 27 (2012), 284–288.
17. [17] Schapira, A.H., McDermott, M.P., Barone, P., Comella, C.L., Albrecht, S., Hsu, H.H., et al. Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. Lancet Neurol. 12 (2013), 747–755.
18. [18] Hughes, A.J., Daniel, S.E., Kilford, L., Lees, A.J., Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 55 (1992), 181–184.
19. [19] Gibb, W.R., Lees, A.J., The progression of idiopathic Parkinson's disease is not explained by age-related changes. Clinical and pathological comparisons with post-encephalitic parkinsonian syndrome. Acta Neuropathol. 73 (1987), 195–201.
20. [20] Calne, D.B., Snow, B.J., Lee, C., Criteria for diagnosing Parkinson's disease. Ann. Neurol. 32:S1 (1992), S125–S127.
21. [21] Zhang, L., Zhang, Z., Chen, Y., Qin, X., Zhou, H., Zhang, C., et al. Efficacy and safety of rasagiline as an adjunct to levodopa treatment in Chinese patients with Parkinson's disease: a randomized, double-blind, parallel-controlled, multi-centre trial. Int. J. Neuropsychopharmacol. 16 (2013), 1529–1537.
22. [22] Hauser, R.A., Molho, E., Shale, H., Pedder, S., Dorflinger, E.E., A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients. Tolcapone De Novo Study Group. Mov. Disord. 13 (1998), 643–647.
23. [23] Mizuno, Y., Abe, T., Hasegawa, K., Kuno, S., Kondo, T., Yamamoto, M., et al. Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study. Mov. Disord. 22 (2007), 1860–1865.
24. [24] Hauser, R.A., Schapira, A.H., Rascol, O., Barone, P., Mizuno, Y., Salin, L., et al. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease. Mov. Disord. 25 (2010), 2542–2549.
25. [25] Poewe, W., Rascol, O., Barone, P., Hauser, R.A., Mizuno, Y., Haaksma, M., et al. Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial. Neurology 77 (2011), 759–766.
26. [26] Strafella, A.P., Ko, J.H., Monchi, O., Therapeutic application of transcranial magnetic stimulation in Parkinson's disease: the contribution of expectation. Neuroimage 31 (2006), 1666–1672.
27. [27] de la Fuente-Fernandez, R., Ruth, T.J., Sossi, V., Schulzer, M., Calne, D.B., Stoessl, A.J., Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 293 (2001), 1164–1166.
28. [28] Lidstone, S.C., Schulzer, M., Dinelle, K., Mak, E., Sossi, V., Ruth, T.J., et al. Effects of expectation on placebo-induced dopamine release in Parkinson disease. Arch. Gen. Psychiatry 67 (2010), 857–865.
29. [29] Goetz, C.G., Janko, K., Blasucci, L., Jaglin, J.A., Impact of placebo assignment in clinical trials of Parkinson's disease. Mov. Disord. 18 (2003), 1146–1149.
30. [30] Hughes, J., Gabbay, M., Funnell, E., Dowrick, C., Exploratory review of placebo characteristics reported in randomised placebo controlled antidepressant drug trials. Pharmacopsychiatry 45 (2012), 20–27.